Recent chatter on X about Medpace Holdings, Inc. (MEDP) has centered around the company's upcoming quarterly earnings report, expected after market close on July 21st. Many users are highlighting analyst expectations of strong revenue and earnings per share, sparking curiosity about whether the company will continue its trend of exceeding market forecasts. The anticipation is palpable as investors await confirmation of growth in the life sciences segment.
Additionally, discussions on X have touched on recent stock price fluctuations, with some noting a dip in share value despite the company's solid historical performance. There’s a mix of optimism about Medpace’s business model and culture, with several voices pointing to its leadership in the biotech sector as a potential driver for future gains. This blend of caution and confidence keeps the conversation dynamic and engaging.
Note: This discussion summary was generated from an AI condensation of post data.
Medpace Holdings, Inc. Insider Trading Activity
Medpace Holdings, Inc. insiders have traded $MEDP stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $MEDP stock by insiders over the last 6 months:
- BRIAN T CARLEY sold 4,003 shares for an estimated $1,383,396
- FRED B JR DAVENPORT sold 1,712 shares for an estimated $516,715
- STEPHEN P EWALD (General Counsel & Corp. Secy.) purchased 2 shares for an estimated $652
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Medpace Holdings, Inc. Hedge Fund Activity
We have seen 277 institutional investors add shares of Medpace Holdings, Inc. stock to their portfolio, and 279 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MAWER INVESTMENT MANAGEMENT LTD. added 696,219 shares (+inf%) to their portfolio in Q1 2025, for an estimated $212,130,967
- CAPITAL WORLD INVESTORS removed 434,736 shares (-99.2%) from their portfolio in Q1 2025, for an estimated $132,459,711
- PROFICIO CAPITAL PARTNERS LLC removed 241,751 shares (-99.7%) from their portfolio in Q1 2025, for an estimated $73,659,112
- VULCAN VALUE PARTNERS, LLC added 224,578 shares (+221.6%) to their portfolio in Q1 2025, for an estimated $68,426,670
- GOLDMAN SACHS GROUP INC removed 159,008 shares (-36.0%) from their portfolio in Q1 2025, for an estimated $48,448,147
- CAMBER CAPITAL MANAGEMENT LP removed 125,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $38,086,250
- KENSICO CAPITAL MANAGEMENT CORP removed 121,100 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $36,897,959
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Medpace Holdings, Inc. Analyst Ratings
Wall Street analysts have issued reports on $MEDP in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 04/09/2025
To track analyst ratings and price targets for Medpace Holdings, Inc., check out Quiver Quantitative's $MEDP forecast page.
Medpace Holdings, Inc. Price Targets
Multiple analysts have issued price targets for $MEDP recently. We have seen 6 analysts offer price targets for $MEDP in the last 6 months, with a median target of $320.5.
Here are some recent targets:
- Luke Sergott from Barclays set a target price of $300.0 on 06/24/2025
- Jailendra Singh from Truist Securities set a target price of $300.0 on 04/23/2025
- Eric Coldwell from Baird set a target price of $313.0 on 04/23/2025
- Charles Rhyee from TD Cowen set a target price of $328.0 on 04/14/2025
- Ann Hynes from Mizuho set a target price of $355.0 on 04/09/2025
- Michael Cherny from Leerink Partners set a target price of $330.0 on 03/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
